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The two main diseases of inflammatory bowel disease are Crohn’s disease and ulcerative colitis. The pathogenesis of in-
flammatory disease is that abnormal intestinal inflammations occur in genetically susceptible individuals according to 
various environmental factors. The consequent process results in inflammatory bowel disease. Medical treatment consists 
of the induction of remission in the acute phase of the disease and the maintenance of remission. Patients with Crohn’s 
disease finally need surgical treatment in 70% of the cases. The main surgical options for Crohn’s disease are divided into 
two surgical procedures. The first is strictureplasty, which can prevent short bowel syndrome. The second is resection of 
the involved intestinal segment. Simultaneous medico-surgical treatment can be a good treatment strategy. Ulcerative 
colitis is a diffuse nonspecific inflammatory disease that involves the colon and the rectum. Patients with ulcerative colitis 
need surgical treatment in 30% of the cases despite proper medical treatment. The reasons for surgical treatment are vari-
ous, from life-threatening complications to growth retardation. The total proctocolectomy (TPC) with an ileal pouch anal 
anastomosis (IPAA) is the most common procedure for the surgical treatment of ulcerative colitis. Medical treatment for 
ulcerative colitis after a TPC with an IPAA is usually not necessary.
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occurs in the colon, and the inflammatory nature is superficial 
and is confined to the mucosa or submucosa. 
The etiology of inflammatory bowel disease is uncertain. Thus, 
epidemiologic studies have been performed to find the reason for 
inflammatory bowel disease. In the United States, Canada, and 
the United Kingdom, the prevalence rate is 300 to 400 per 100,000 
population. However, in Japan and Singapore, the prevalence rate 
is smaller than it is in the Western countries. The prevalence rate 
of inflammatory bowel disease is 23 per 100,000 population in 
Japan, and 10 per 100,000 population in Singapore. Moreover, 
Africa and South America have relatively low prevalence rates 
compared to the Western countries [3-6].
In Korea, there is a lack of nationwide epidemiologic data for the 
prevalence rate of inflammatory bowel disease. Recently, Yang et 
al. [7] reported that the adjusted prevalence rate of inflammatory 
bowel disease was 30.87 per 100,000 population for specific urban 
regions in the area of Seoul. This datum was similar to the data for 
other Asian countries (Japan and Singapore). In the study of Yang 
et al. [7] the prevalence rate increased from 11.24 per 100,000 pop-
ulation during 1986 to 1990 to 30.87 per 100,000 population dur-
ing 2001 to 2005. Korea was developing and becoming urbanized 
during those study periods. These results imply that urbanization 
INTRODUCTION
Inflammatory bowel disease was officially reported with the name 
of ‘regional ileitis’ in 1932 by Crohn et al. [1]. However, a disease 
which could be considered as Crohn’s disease retrospectively was 
first reported in 1813 [2]. 
The two main diseases of inflammatory bowel disease are Crohn’s 
disease and ulcerative colitis. Inflammatory bowel disease has a 
wide range of manifestations from acute to chronic in nature and 
a wide involvement of lesions from the mouth to the anus. Crohn’s 
disease shows a typically transmural inflammatory nature and in-
volves both the small intestine and the colon. Ulcerative colitis 
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may be a risk factor for inflammatory bowel disease.   
PATHOGENESIS OF INFLAMMATORY 
BOWEL DISEASE AND MEDICAL 
TREATMENT
According to epidemiologic studies, the etiologies of inflamma-
tory bowel disease include not only genetic factors but also envi-
ronmental factors. As environmental factors, enteric microbes, 
flagellin, diet and smoking have been recognized as etiologic fac-
tors. Smoking has been clearly considered as a definite etiologic 
factor for developing Crohn’s disease de novo and for increased 
recurrence after surgical treatment [8]. Moreover, hygiene, diet 
and antibiotics have been considered as environmental factors [9].
Genetic factors have been a major research area to evaluate the 
pathogenesis of inflammatory disease. As a genetic predisposition, 
NOD2/CARD15, IL-23 receptor, OCTN 1 and 2, DLG5, HLA, 
ATG16L1 and others are considered [8, 10, 11]. NOD2/CARD15 
was discovered in 2001. NOD2/CARD15 is on chromosome 16 
and is expressed as a cytoplasmic protein. Its role is recognition of 
muramyl dipeptide, a component of the bacterial cell wall pepti-
doglycan, and activation of NF-kappa B, a potent second messen-
ger involved in immune regulatory mechanisms [12]. Genetic 
mutation of NOD2 causes an abnormal recognition of commen-
sal bacteria in the intestinal lumen. Then, the innate immune sys-
tem is impaired. Subsequently, abnormal inflammation occurs in 
the intestinal wall and results in the destruction of the mucosa. 
However, this hypothesis covers only 25% of the pathogenesis of 
Crohn’s disease in Caucasians. Moreover, ulcerative colitis is not 
related to the mutation of NOD2 [13]. 
Thus, current understanding of the pathogenesis of inflamma-
tory disease is that abnormal intestinal inflammations occur in 
genetically susceptible individuals because of various environmen-
tal factors such as diet, hygiene and drugs. The consequent pro-
cess results in inflammatory bowel disease [14]. 
Medical treatment consists of the induction of remission in the 
acute phase of the disease and maintenance of remission. The pur-
pose of proper treatments is to prevent complications from both 
the disease itself and the long-term medical treatment and to im-
prove the quality of life by symptom control and prevention of 
complications. These purposes can be achieved by precise medi-
cal treatments and proper use of surgical treatments. 
Sulfasalazine and 5-aminosalicylates are the first line drugs for 
mild-to-moderate Crohn’s disease. Metronidazole and ciprofloxa-
cin can be used as additional medical treatments for perianal com-
plications of Crohn’s disease. However, side effects occur in 50% 
of the patients who take metronidazole. The side effects of metro-
nidazole are indigestion, metallic taste, reaction to alcohol, and 
peripheral neuropathy. Peripheral neuropathy can be irreversible 
and occurs in patients with long-term use of metronidazole. Cip-
rofloxacin can be as effective as 5-aminosalicylic acid for the remis-
sion of Crohn’s disease [15]. Corticosteriods, biologic agents and 
immunomodulators can be used for moderate-to-severe Crohn’s 
disease. Corticosteriods are effective for the induction of remis-
sion, but are not indicated for maintenance therapy in Crohn’s 
disease.  
Immunomodulators that are often used for the medical treat-
ment of Crohn’s disease are azathioprine (AZA), 6-mercaptopu-
rine (6-MP) and methorexate (MTX). AZA and 6-MP are useful 
for maintaining remission, and MTX can be used for the induc-
tion of remission. Infliximab is a tumor necrosis factor, an antago-
nist as a biologic agent, and is effective in both the induction of 
remission and the maintenance of remission. Especially, inflix-
imab is effective in fistulizing Crohn’s disease [16-18]. 
 Sulfasalazine and 5-aminosalicylates are the first line agents for 
the induction of remission in mild-to-moderate ulcerative colitis, 
like Crohn’s disease. In the treatment of ulcerative colitis, cortico-
steroids can be used for the induction of remission. AZA and 6-MP 
are used if the disease is persistently active and steroid refractory. 
Infliximab is the only biologic agent that is effective in treating 
ulcerative colitis and can be used for both the induction of remis-
sion and the maintenance of remission in patients with moderate-
to-severe ulcerative colitis [19]. Cyclosporin and infliximab can 
be used as rescue therapy for severe steroid-refractory ulcerative 
colitis [20]. 
SURGICAL MANAGEMENT OF 
INFLAMMATORY BOWEL DISEASE
Crohn’s disease
Patients with Crohn’s disease finally need surgical treatment in 
70% of the cases and will require re-operations in 30 to 70% of the 
cases [21, 22]. The first line of treatment has been proper medical 
treatment because of its chronic inflammatory nature. However, 
medical treatment alone cannot manage the entire prolonged 
course of Crohn’s disease. Surgical intervention is a critical and 
mandatory treatment option to manage complicated Crohn’s dis-
ease. Indications of surgery for Crohn’s disease are hemorrhage, 
intestinal perforation, intestinal obstruction and abscess. These 
indications usually need emergent operations in cases with severe 
colitis. Indications for an elective operation are a neoplasm from 
Crohn’s disease, complications that have a chronic nature, growth 
retardation, and failed medical treatments. Failed medical treat-
ments can be divided into non- or limited-responsive disease in 
the following situations: the patient’s not being able to endure the 
symptoms related to Crohn’s disease, the existence of problematic 
complications related to the medications for Crohn’s disease, and 
the patient’s poor compliance with the medication.  
 
Surgery options
The main surgical options for Crohn’s disease are divided into two 
surgical procedures. The first is strictureplasty, which can prevent 
short bowel syndrome. The second is resection of the involved 
intestinal segment. Both procedures can be performed using the 
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open or the laparoscopic approach. Strictureplasty cannot be per-
formed for patients with active Crohn’s disease, phlegmon, septic 
fistulas, and duodenal strictures. Moreover, if the stricture site is 
a previous anastomosis site and recurrence occurs within 12 months 
of the previous operation, strictureplasty is not a proper surgical 
treatment option [23-26]. Perforation and severe malnutrition 
(albumin < 2.0 g/dL) are also contraindications of strictureplasty 
[23]. Without these contraindications, if the length of the remain-
ing bowel is anticipated to be smaller than 1 to 2 m, strictureplasty 
should be considered to avoid short bowel syndrome [27]. 
Many methods are used to perform strictureplasty. The most 
common method is the Heineke-Mikulicz strictureplasty. This 
method is a relatively easy method and can be adopted effectively 
by the general surgeon because it is the original surgical procedure 
for the treatment of duodenal peptic ulcer disease. The Heineke-
Mikulicz strictureplasty is appropriate for a short segment stric-
ture (<10 cm) [28, 29]. A longitudinal enterotomy is performed 
along the stricture segment beyond 2 cm. Then, primary closure 
is performed in a vertical direction. This method of closure per-
mits a proper lumen after the operation. 
Other strictureplasties similar to the Heineke-Mikulicz stricture-
plasty are the Judd stictureplasty and the Moskel-Walske-Neu-
mayer strictureplasty. If a fistulous opening exists in the segment 
of a stricture, the Judd strictureplasty is performed. In this proce-
dure, the fistulous opening is first excised. Then, a longitudinal 
entrotomy is performed horizontally across the excised fistulous 
opening, and primary repair is performed in the same manner 
as in the Heineke-Mikulicz strictureplasty. In the Moskel-Walske-
Neumayer strictureplasty, a Y-shaped enterotomy is performed 
horizontally with the strictured segment. Closure of the Y-shaped 
enterotomy is similar to the Heineke-Mikulicz strictureplasty. 
These types of strictureplasties are for short segment strictures 
(<10 cm) [30].
If the length of the strictured segment is longer than 10 cm and 
shorter than 25 cm, intermediate strictureplasties are proper sur-
gical options. These procedures are the Finney strictureplasty and 
the Jaboulay strictureplasty. In the Finney strictureplasty, the stric-
tured segment is folded into a U shape, an enterotomy is performed 
along the folded U shape segment, and a side-to-side anastomosis 
is performed [30-32]. If the enterotomy is linear at both sides with-
out a connection and side-to-side anastomosis is done, the method 
is called a Jabloulay strictureplasty [29]. 
The Michelassi strictureplasty and the Poggioli stictureplasty are 
the surgical procedures for long strictured segments of the bowel 
(>20 cm). In the Michelassi strictureplasty, the first procedure is 
cutting the mid portion of the long strictured segment and then 
overlapping each strictured segment. Then, a side-to-side longitu-
dinal enteroenterostomy is performed. This procedure is a side-
to-side isoperistaltic strictureplasty. The Poggioli strictureplasty is 
a modified type of Michelassi strictureplasty. The difference is in 
the cutting area. The cutting area is the distal area of the strictured 
segment. This procedure is side-to-side isoperistatlic similar to the 
Michelassi strictureplasty, and the diseased to the diseased-free 
enterostomy is different from the Michelassi strictureplasty. 
The surgical field and condition of Crohn’s disease is frequently 
difficult due to severe mesenteric inflammation, stricture, fistula, 
abscess and adhesion. In these conditions, surgeons prefer resec-
tion of the involved segment because of the possibility of rapid 
reactivation of Crohn’s disease and anastomotic failure. However, 
the safety and the feasibility of strictureplasty have been noted [23, 
24, 33-35]. 
Resection of the involved bowel is necessary if strictureplasty is 
not technically appropriate or indicated. Minimal invasive surgi-
cal procedures can be used for the surgery of Crohn’s disease. Lap-
aroscopic surgery is an available option for minimal invasive sur-
gery. The benefits of laparoscopic surgery are a shorter hospital 
stay and better cosmetics compared to conventional open surgery. 
The median hospital stay of laparoscopic surgery was 5 days in 
the Maartense et al. [36] and the Milsom et al. [37] studies. In the 
Maartense et al. [36] study, the median hospital stay of open sur-
gery was 7 days, and the hospital stay of laparoscopic surgery was 
shown to be significantly shorter than the hospital stay of conven-
tional surgery. However, the difference in the length of stay between 
the two groups was not significant in the Milsom et al. [37] study. 
In the Milsom et al. [37] study, the median hospital stay was 6 days. 
The wound infection rates and the incidences of postoperative 
pneumonia were not different between the groups in these stud-
ies. Other studies have also reported on the safety and the feasibil-
ity of laparoscopic surgery [38, 39].
A valuable benefit of laparoscopic surgery is the shorter length 
of the skin incision. Crohn’s disease patients are relatively younger 
than cancer patients. Thus, this cosmetic advantage of laparoscopic 
surgery can be valuable. However, the procedure of laparoscopic 
surgery is limited compared to conventional surgery. Laparoscopic 
surgery can be challenging if the surgical field has one or more of 
the following: advanced and severe mesenteric inflammation, an 
entero-enteric fistula, an entero-cutaneous fistula, or an abscess 
with severe fibrotic adhesion. Open conversion is frequently nec-
essary in these situations. A delayed operation may result in the 
patient’s losing the opportunity to receive minimally invasive sur-
gery. This is unfortunate because minimally invasive surgery has 
better cosmetics after surgery compared to conventional open sur-
gery. Besides laparoscopic surgery, single-port laparoscopic sur-
gery (SILS) has been recently adopted in surgery for Crohn’s dis-
ease. Laparoscopic surgery has multi-ports compared to SILS. Thus, 
SILS has better cosmetics than laparoscopic surgery, but more 
limitations during the procedure than laparoscopic surgery [40].
Robotic surgery is another option for minimally invasive sur-
gery. It can be used for Crohn’s disease because robotic surgery 
has been used for rectal cancer surgery and has the same concepts 
as laparoscopic surgery. However, adoption of robotic surgery is 
questionable due to the high cost of robotic surgery. To date, no 
report on robotic surgery for Crohn’s disease has been found. 
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Perianal Crohn’s disease
In Crohn’s disease, many pathologic anal lesions are related to 
Crohn’s disease. These are perineal ulcerations, anal fissures, anal 
stenoses, anorectal abscesses, rectovaginal fistulas and perianal 
fistulas. These perianal diseases occur in up to 90% of Crohn’s dis-
ease patients, and initial isolated perianal manifestation is observed 
in 10 to 15% of the patients [41, 42]. Unusual perianal ulcers may 
occur in 1.9 to 5.1% of the patients with Crohn’s disease [43]. 
Anal fissures occur at any location of the anus and are different 
from ordinary anal fissures, which occur at the posterior or ante-
rior midline of the anus. The most common lesion is posterior 
(41%), and multiple fissures occur in 32 to 33% of the patients. 
Lateral fissures occur in 9 to 20% of the patients. Anal pain is rela-
tively less than it is for an ordinary anal fissure [41-43]. Conserva-
tive treatment is the first option. A lateral internal sphincterotomy 
can be applied to an intractable anal fissure [44]. 
Anal stenoses are common in patients with Crohn’s disease. 
There are two etiologies of anal stenosis. The first is infection 
and inflammation of an intraluminal membrane or extramucosal 
fibrotic tissue. One finger dilatation or a Hegar dilator can be used 
for maintaining proper defecation in patients with severe anal ste-
nosis. However, a proctectomy may be necessary in some severe 
cases [45]. 
Anorectal abscesses occur with an incidence of 23 to 62% in the 
natural history of Crohn’s disease. They are a relatively common 
manifestation of Crohn’s disease, and 70% of the anorectal abscesses 
are related to perianal fistulas [43].
Rectovaginal fistulas are a problematic manifestation of Crohn’s 
disease. They occur spontaneously in 3.5 to 23% of patients with 
Crohn’s disease. A minimal symptomatic rectovaginal fistula may 
not need operative treatment. A symptomatic fistula without proc-
titis can be treated by local repair. A symptomatic fistula with severe 
proctitis usually needs a proctectomy. In this situation, local repair 
with a fecal diversion can be another treatment option [46, 47]. 
Perianal fistulas
Perianal fistulas are a very problematic condition that decreases 
the quality of life in Crohn’s disease patients. The incidence of 
perianal fistulas in Crohn’s disease patients is reported to be 14 to 
56%. Moreover, perianal fistulas can be the first clinical manifes-
tation of Crohn’s disease [48-50]. Clinical manifestations of peri-
anal fistulas are prolonged pus drainage from an external opening 
of a perianal fistula. Perianal pain can accompany a perianal fistula 
because a perianal abscess can progress even though some part of 
the pus is drained through an external opening. In this situation, 
proper abscess drainage is usually necessary.  
A conventional fistulotomy or fistulectomy should be applied 
with great attention because the postoperative wound is usually 
unhealed. Bell et al. [51] reported that the median healing time 
was up to 2.6 years after the operation. Intersphincter fistulas and 
low transsphincter fistulas can be treated safely without a high risk 
of postoperative incontinence by using a fistulotomy [52]. Mid 
and high transsphincter fistulas should not be treated by using a 
fistulotomy or a fistulectomy due to postoperative incontinence. 
Postoperative fecal incontinence after a fistulotomy or a fistulec-
tomy occurs in over 50% of the cases. In this situation, the loose 
seton procedure is the favored surgical option. Seton is the thread 
that goes into the external opening through the fistula tract and 
that goes out from the internal opening and is linked with both 
ends. There are two kinds of seton procedures. They are the loose 
seton and the cutting seton. The loose seton is a favored procedure 
for Crohn’s disease patients. The seton materials are usually silk, 
nylon, rubber, silicon, etc. The function of the seton is to maintain 
proper pus drainage continuously and to prevent perianal abscess 
formation. Long-term drainage using a seton is necessary. Recur-
rence after a seton removal occurs in 39% of the cases. Thus, in 
some cases, permanent seton drainage is required [53, 54]. 
Mucosal advancement flaps can be used for complex fistulas. 
The success rates of mucosal advancement flaps have been re-
ported to be 55 to 98% [55-60]. However, a high recurrence rate 
was reported. Mizrahi et al. [55] reported that recurrence after a 
muscosal advancement flap replacement was 57% in patients with 
Crohn’s disease, with a follow-up period of 40.3 months. 
Recently, adipose-derived stem cell implantation has been intro-
duced as an experimental treatment option for perianal fistulas 
related to Crohn’s disease. Garcia-Olmo et al. [61] reported that 
stem cell implantation in combination with fibrin glue was more 
effective than fibrin glue alone in patients with a suprasphinteric 
fistula and that it was shown to be safe and effective for the treat-
ment of complex perianal fistulas. However, the number of cases 
in these studies was less than 13. Thus, large-scale prospective 
clinical trials are necessary to commonly adopt stem cell implan-
tation as a treatment method for perianal fistulas related to Crohn’s 
disease [62]. 
Medical treatment
Medical treatment of perianal Crohn’s disease cannot be underes-
timated. Surgical treatments have limitations as mentioned above. 
Thus, simultaneous medico-surgical treatment can be a good treat-
ment strategy. Antibiotics, anti-tumor necrosis factor-a antibody 
agent, and immunomodulators are main medical treatment agents. 
Antibiotics like metronidazole and ciprofloxacin are used. Metro-
nidazole is an antibiotic that fights against anaerobic bacteria in-
fection. Perianal fistulas in patients with Crohn’s disease have a 
colonization of anaerobic bacteria. Because of this, metronidazole 
is the first drug treatment for Crohn’s-disease-related perianal fis-
tulas [63]. The treatment success rates for perianal fistulas in pa-
tients with Crohn’s disease using metronidazole ranged from 34 
to 83% [64-68]. However, discontinuation of metronidazole re-
sulted in recurrence even though it had been administered long 
term (6 to 8 weeks) [64, 68]. There are various side effects such as 
a metallic taste, glossitis, nausea and severe peripheral neuropathy 
with long-term use of metronidazole [66].
Ciprofloxacin is an alternative antibiotic to metronidazole. Cip-
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rofloxacin is a quinolone antibiotic and is effective against gram-
negative bacteria. The side effects of ciprofloxacin are relatively 
less than those of metronidazole. However, complete closure of 
the perianal fistula is very rare, and recurrence occurs after dis-
continuation of ciprofloxacin [69].
Infliximab is not only an effective drug for the maintenance treat-
ment for Crohn’s disease but also can be used for the treatment of 
perianal fistulas in patients with Crohn’s disease. Present et al. [16] 
reported that the closure of fistulas was noted in 46% of the cases 
after a median of 12 weeks [18]. Immunomodulators, such as tacro-
limus, cyclosporine, and AZA can be used for medical treatment 
of perianal fistulas in patients with Crohn’s disease. However, these 
immunomodulators have serious side effects, such as an opportu-
nistic infection and reactivation of a latent infection, as with inf-
liximab. Thus, long-term medical treatment only for perianal fis-
tulas in patients with Crohn’s disease is controversial [70, 71].
Surgical and medical treatments have some roles in the treat-
ment of perianal fistulas in patients with Crohn’s disease. How-
ever, the treatment results are not satisfactory, and there are limi-
tations because of the surgical and the medical complications from 
those treatment modalities. Thus, there have been endeavors to 
find other treatment methods. Recently, biomaterials have been 
introduced for the treatment of perianal fistulas in patients with 
Crohn’s disease. These biomaterials are fibrin glue, BioGlue, colla-
gen-based tissue adhesives, and collagen plugs [72-76].
Initial experiences using fibrin glue were acceptable, with a high 
success rate of 60 to 85% [72, 77-82]. However, these success rates 
were not repeated in subsequent studies [72, 81-84]. Vitton et al. 
[85] reported that the closure of fistulas was observed in only 14% 
of patients 3 months after treatment. BioGlue reported a 50% suc-
cess rate in the treatment of Crohn’s-related perianal fistulas. How-
ever, it may cause serious nerve injury [73]. Collagen-based tissue 
adhesives and collagen fistula plugs are relatively safe biomaterials 
compared to fibrin glue in terms of disease transmission because 
they are manufactured from porcine dermis [74]. Collagen-based 
tissue adhesive has limited data for the treatment of perianal fistu-
las in patients with Crohn’s disease, and the success rate of the col-
lagen fistula plug is from 24 to 87% [75, 86].
Intraabdominal pyogenic complications
Intraabdominal abscesses or pelvic abscesses occur at some point 
in 10 to 30% of patients with Crohn’s disease throughout the whole 
natural history of the disease [87-89]. Intraabdominal abscesses, 
which occur in patients with Crohn’s disease, show a chronic na-
ture, and simultaneously entero-enteric, entero-peritoneal and 
entero-cuataneous fistulas can occur. Even though these abscesses 
rarely cause an acute septic condition, adequate drainage is neces-
sary. Definitive surgical resection of the involved bowel is the tra-
ditional standard surgical treatment after abscess drainage. How-
ever, because of the development of minimally invasive interven-
tional treatment, the drainage-only procedure has been introduced 
as the proper treatment option for intraabdominal abscesses in 
patients with Crohn’s disease [90-92]. However, the drainage of 
the abscess has limitations. One-third of the patients who under-
went drainage of the abscess needed a second surgical treatment 
after a one-year followup [93]. Other studies have reported that 
interventional percutaneous drainage as the only treatment for an 
intraabdominal abscess is successful in only about 50% of Crohn’s 
disease patients [91, 92, 94-99].
Neufeld et al. [93] reported that 13 patients who received percu-
taneous or surgical drainage procedures due to abdominal wall 
abscesses eventually needed resection of the involved bowel seg-
ment. They found that surgical resection was necessary despite 
initial adequate drainage and concluded that surgical resection of 
the diseased bowel segment should be the definitive treatment ac-
cording to their experiences. Poritz and Koltun [100] suggested a 
multimodal combined treatment protocol that consisted of initial 
proper percutaneous drainage with antibiotic and steroid admin-
istration, followed by a planned resection with a primary anasto-
mosis. They suggested that this protocol provided standard care 
for the treatment of intraabdominal abscesses in Crohn’s disease 
patients.
ULCERATIVE COLITIS
Ulcerative colitis is a diffuse nonspecific inflammatory disease 
that involves the colon and the rectum. The depth of inflamma-
tion is confined to the mucosa and the submucosa, which is dif-
ferent from Crohn’s disease, which shows transmural inflamma-
tion. Typical clinical manifestations are diarrhea, abdominal pain, 
fever, weight loss and hematochezia. Clinical manifestations show 
both an acute and a chronic nature. Moreover, clinical the spec-
trum ranges from inactive to fulminant disease and is dynamic, 
ranging from remission to exacerbation. Chronic clinical mani-
festations of ulcerative colitis can be divided into mild, moderate, 
and severe disease. Frequency of bowel movements, rectal bleed-
ing, hemoglobin, ESR, body temperature and heart rate are used 
as parameters in categorizing the severity [101, 102].
The small bowel is not involved in ulcerative colitis. However, 
the diarrheal contents of the cecum can reflux into the terminal 
ileum; then, the terminal ileum becomes inflamed, which is called 
‘back-wash ileitis’ and shows a reversible nature. Backwash ileitis 
should be differentiated from the ileitis of Crohn’s disease. 
Ulcerative colitis has extra-colonic manifestations. Asymptom-
atic parenchymal liver disease is the most common manifestation 
[103]. Fatty infiltration is observed in up to 50% of patients with 
ulcerative colitis, and liver cirrhosis can also be present in 3 to 4% 
of patients with ulcerative colitis [104, 105]. Primary sclerosing 
cholangitis is another hepatobiliary manifestation of ulcerative 
colitis. Arthritis, ankylosing spondylitis, and sacroiliitis are extra-
colonic manifestations of the bone and joints. As dermatologic 
manifestations, erythema nodosum and pyoderma gangrenosum 
can be observed in both ulcerative colitis and Crohn’s disease. Ery-
thema nodosum occurs in 10 to 15% of patients with both ulcer-
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ative colitis and Crohn’s disease. Pyoderma gangrenosum is rare, 
but serious [106].
Patients with ulcerative colitis need surgical treatment in 30% of 
the cases, despite proper medical treatment [107]. The reasons for 
surgical treatment are various, ranging from life-threatening com-
plications to growth retardation. The indications for surgery can 
be divided into two categories, elective and emergency, according 
to the need for emergent surgery. Indicators of elective surgery are 
refractory disease status to medical treatment, complications and 
side effects of chronic medical treatment, intestinal dysplasia or 
mass lesion, colorectal cancer, severe extra-colonic manifestation, 
stricture formation and growth retardation. Among these indica-
tors of elective surgery, in fact, refractory disease status for medi-
cal treatment is difficult to define. Patients can feel their status is 
medically intractable because of too much loss of their opportuni-
ties to perform everyday or valuable works in their lives due to 
symptoms related to ulcerative colitis even though the physician 
is still considering other medical treatment strategies. In this situ-
ation, elective surgery should be decided appropriately. Definitely, 
the converse situation also can occur. However, problematic com-
plications and surgical treatment options should be provided to 
the patients and their families.
The overall prevalence rate of colorectal cancer is approximately 
3.7% in patients with ulcerative colitis [108]. The risk of colorectal 
cancer rises rapidly 10 years after exposure to ulcerative colitis. The 
risk of colorectal cancer is 50% after 30 years of the disease and 
75% after 40 years of the disease [109]. Colorectal cancer and high-
grade dysplasia are clear indicators of surgery. Dysplasia is graded 
into high-grade dysplasia and low-grade dysplasia according to 
the degree of cytologic and architectural alteration [110, 111]. 
Low-grade dysplasia is controversial due to its relatively low risk 
of cancer development compared to high-grade dysplasia. How-
ever, surgical treatment should be considered in young patients 
with ulcerative colitis who have a long life expectancy. Pathologic 
diagnosis of dysplasia is a very difficult task. Thus, at least two dif-
ferent experienced pathologists are necessary for the proper diag-
nosis of dysplasia [112].
Extra-colonic manifestations are indicators of elective surgery in 
patients with ulcerative colitis. Arthritis, uveitis, and iritis are im-
proved favorably after a colectomy. However, primary sclerosing 
cholangitis, ankylosing spondylitis, and sacroilitis are not improved 
even though a colectomy is performed [106, 113].
Indicators of emergent surgery are a toxic megacolon, perforation, 
uncontrolled rectal bleeding, septic condition or fulminant disease 
activity despite intensive medical treatment. In an emergent situa-
tion, the standard surgical option is a subtotal colectomy with an 
end ileostomy. This procedure is technically easier than a total proc-
tocolectomy (TPC) with an ileal J-pouch anal anastomosis, which 
is performed in an elective situation. A subtotal colectomy with 
an end ileostomy can achieve proper disease control for a septic 
condition due to toxic complications of ulcerative colitis. More-
over, a future restorative procedure is possible. However, if mas-
sive bleeding is focused in the rectum, then a proctectomy is nec-
essary. Laparoscopic or hand-assisted laparoscopic surgery is fea-
sible and safe in this situation. However, in critically ill patients, 
adopting laparoscopic surgery is controversial because this surgi-
cal procedure significantly increases the duration of the operation 
[114, 115].
As elective surgical treatments, there are four main surgical op-
tions. The first is the TPC with a Brooke ileostomy, and the sec-
ond is a TPC with an ileal pouch anal anastomosis (IPAA) (TPC 
with IPAA). An abdominal colectomy with an ileorectal anasto-
mosis and a TPC with a continent ileostomy are the third and the 
fourth surgical options, respectively. A TPC with a Brooke ileos-
tomy (primary maturation of the ileostomy) has been the ‘golden 
standard surgical option’ because the entire diseased colon and 
rectum can be removed with low complications compared to other 
surgical options [116]. The permanent ileostomy is a disadvantage 
though. The patient should be educated preoperatively about changes 
in the body image and lifestyle. Recently, indicators of this proce-
dure are elderly patients, patients with distal rectal cancer, preop-
erative poor anal sphincter function, which anticipates poor func-
tional outcomes after sphincter-saving surgery, and patients who 
accept this procedure after preoperative education [116].
An abdominal colectomy with an ileorectal anastomosis is the 
rectum and anal-sphincter-saving procedure. If the rectum is not 
diseased preoperatively, this procedure can be performed. How-
ever, regular postoperative colonoscopic examinations should be 
performed to detect dysplasia or rectal cancer in the remaining 
rectum. The risk of rectal cancer is approximately 5% in 15 to 20 
years [117]. Young patients who want to return to work or want 
to preserve their reproductive abilities are candidates for this pro-
cedure. However, if patients have inflammation of the rectum or 
compromised anal sphincter function, this procedure cannot be 
used. The continent ileostomy was introduced by Kock [118]. This 
procedure is a surgical solution for patients who do not wish to 
attach an ostomy appliance and who do not want a Brooke ileos-
tomy. However, postoperative complications are problematic in 
this procedure. Vernava and Goldberg [119] reported that early 
complication rates were 23% and that late complication rates were 
54%. In that study, they categorized intraabdominal abscesses, 
peritonitis, suture line leakages, fistulas, small bowel obstructions, 
and stomal necrosis as early complications and valve dysfunction 
requiring another operation as a late complication. Thus, recently, 
the use of this procedure has been very rare.
TPC with IPAA is the most common procedure for surgical treat-
ment of ulcerative colitis because the body image does not change 
and the anal route of defecation is preserved. TPC with IPAA has 
four phases: removal of the colon and rectum while sparing the 
pelvic nerve and the anal sphincter function and constructions of 
an ileal reservoir, an ileal reservoir anal anastomosis and diverting 
ileostomy. The diverting ileostomy is generally recommended even 
though fecal diversion cannot prevent anastomotic leakage because 
it can prevent severe septic complications due to a large amount 
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of fecal leakage into the pelvic cavity [120, 121]. The ileal reservoir 
is an ileal pouch, and there are several types of ileal pouches. The 
S pouch was introduced in 1978 by Parks and Nicholls [122], and 
the J pouch was described by Utsunomiya et al. [123] in 1980. Re-
cently, the J pouch has been the ileal pouch most preferred by al-
most all surgeons [124].
Medical treatment for ulcerative colitis after a TPC with IPAA is 
not necessary. However, pouchitis can occur after the operation, 
and the incident rate of pouchitis is 7 to 59% [125-127]. Other 
pouch-related complications can occur, and these are anastomotic 
strictures, perianal fistulas, perianal abscesses, abdominal fistulas, 
abdominal or pelvic abscesses, and unsatisfactory function of the 
pouch. The incidence rates of these complications are 12 to 22% 
[128, 129].
Sexual and voiding dysfunctions may occur because pelvic nerve 
injury may occur during the proctectomy. Postoperative impotence 
occurs in 1 to 2% of the patients and retrograde ejaculation in 2 to 
3% of the patients. Dyspareunia occurs in 7% of the patients and 
fecal leaks during sexual intercourse in 2% of the patients [130-132].
The most problematic complication, which decreases the quality 
of life, is the ileal pouch vaginal fistula. The incidence rate of the 
ileal pouch vaginal fistula is 4 to 12% [133-138]. The ileal pouch 
vaginal fistula can persist even though repeated surgical attempts 
for closure are performed. The success rate of surgical treatment 
of an ileal pouch vaginal fistula is approximately 50% in patients 
with an initial failure of surgery [139]. Moreover, Shah et al. [140] 
reported eventual pouch failure in 22% of the patients and persis-
tent pouch-vaginal fistulas in 27% of the 60 female patients who 
had a pouch-vaginal fistula after an IPAA.
INDETERMINATE COLITIS
Indeterminate colitis is a third disease entity among the inflam-
matory bowel diseases and was introduced by a pathologist [141]. 
However, the definition of indeterminate colitis is still controver-
sial. Moreover, it can be considered as a non-disease entity and 
has no specific diagnostic criteria. Generally, indeterminate colitis 
is defined as an inflammatory bowel disease when the diagnostic 
criteria of either ulcerative colitis or Crohn’s disease cannot be 
matched. Clinical, endoscopic, radiologic and pathologic infor-
mation should be evaluated for the diagnosis of indeterminate 
colitis. The portion of indeterminate colitis among inflammatory 
bowel diseases is about 5%, and other studies have reported prev-
alence rates from 1 to 20% [142-145].
Clinical manifestations of indeterminate colitis are more severe 
than those of ulcerative colitis and Crohn’s disease and are related 
to fulminant ulcerative colitis. In the surgical aspect, indetermi-
nate colitis should be attended to because it has a higher tendency 
of a colectomy, postoperative complications, and pouch failure after 
an IPAA [146]. 
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